The CAR-T landscape is replete with different permutations of the technology that are often arcane and difficult to grasp for even seasoned investors. Each formulation has its own advantages and disadvantages critical to understand in order to get a decent hold on a company’s long term viability in this area. The combination of the clinical data so positive yet so unproven in the market can get traders caught in honey traps.
At this point, a company associated with CAR-T is almost expected to show stellar efficacy data in its trials, so buying in on efficacy